Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-10 and TT-4 in Advanced Selected Solid Tumors
NCT04969315Phase 2Recruiting
- Sponsor
- Portage Biotech
- Start
- Jun 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TT-10 and PORT-7 in renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC) and 1 more (3 cohorts), sponsored by Portage Biotech. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 1 year and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
TT-10PORT-7
03
Conditions
renal cell carcinoma (RCC)castration-resistant prostate cancer (CRPC)non-small cell lung cancer (NSCLC)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04969315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969315.